Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

about

Hyper-Prolactinemia in Men With Idiopathic Dilated Cardiomyopathy: Does It Have any Prognostic Implications?Assessment of serum prolactin levels in acute myocardial infarction: The role of pharmacotherapy

P2860

Q34621270-5508DB8A-C7CB-4209-8D23-B54FD61CD137 Q36550324-1671577D-5FCF-4553-9916-F04E2DF42663

P2860

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

Item

http://www.wikidata.org/entity/Q35968131

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

@ast

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

@en

type

Item

label

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

@ast

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

@en

prefLabel

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

@ast

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

@en

P1476

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

@en

P2093

Jubbin J Jacob

http://www.w3.org/2001/XMLSchema#string

Prashant Paul Verghese

http://www.w3.org/2001/XMLSchema#string

Sandeep Chopra

http://www.w3.org/2001/XMLSchema#string

P2860

Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review.

Peripartum cardiomyopathy: recent insights in its pathophysiology.

The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells.

Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature.

Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches.

Myocardial infarction postpartum in patients taking bromocriptine for the prevention of breast engorgement.

Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study.

Poor outcome of indigent patients with peripartum cardiomyopathy in the United States.

Recovery from peripartum cardiomyopathy after treatment with bromocriptine.

Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine.

P304

S60-2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2230-8210.94261

http://www.w3.org/2001/XMLSchema#string

P478

16 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22701847

http://www.w3.org/2001/XMLSchema#string

P932

3354950

http://www.w3.org/2001/XMLSchema#string

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

about

P2860

P2860

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932